Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018

被引：0
|
作者：
Mónica Mejía-Ochoa
Paola Andrea Acevedo Toro
Jaiberth Antonio Cardona-Arias
机构：
[1] Laboratorio Médico de referencia,Molecular Hematopathology Research Group, School of Microbiology,University of Antioquia
[2] University of Antioquia,Molecular Hematopathology Research Group, School of Microbiology
[3] Cooperativa Universidad de Colombia,School of Microbiology University of Antioquia, School of Medicine
来源：
BMC Cancer | / 19卷
关键词：
Myeloproliferative disorders; Mutation; Polycythemia vera; Essential thrombocythemia; Primary myelofibrosis; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] THE INFLUENCE OF JAK2 V617F, CALRETICULIN AND MPL MUTATION ON PLATELET ADHESION UNDER FLOW CONDITION IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
    Vignoli, A.
    Tessarolo, S.
    Marchetti, M.
    Gamba, S.
    Piras, F.
    van der Meijden, P. E.
    Swieringa, F.
    ten Cate, H.
    Finazzi, G.
    Heemskerk, J. W.
    Rambaldi, A.
    Falanga, A.
    HAEMATOLOGICA, 2015, 100 : 27 - 27
  • [42] Clinical utility of ARMS-PCR amplification-refractory mutation system for the detection of JAK2 gene variations [JAK2 haplotypes] in myeloprohferative disorders [polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Tabuk
    Mir, Rashid
    Abu-Duhier, F. M.
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (03): : 5796 - 5803
  • [43] Comparison of CALR Mutation Testing on Peripheral Blood To Paraffin Embedded Bone Marrow Tissue in Nonmutated JAK2 Primary Myelofibrosis and Essential Thrombocythemia
    Menke, Joshua
    Chehab, Farid
    Prokash, Sonam
    MODERN PATHOLOGY, 2015, 28 : 363A - 363A
  • [44] Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Giles, Jennifer L. K.
    Pitou, Celine
    Zimmermann, Annamaria Hayden
    Price, Gregory L.
    Walgreen, Richard A.
    Prchal, Josef
    BLOOD, 2013, 122 (21)
  • [45] A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
    B Bellosillo
    L Martínez-Avilés
    E Gimeno
    L Florensa
    R Longarón
    G Navarro
    A Salar
    B Espinet
    F Solé
    S Serrano
    C Besses
    Leukemia, 2007, 21 : 1331 - 1332
  • [46] Comparison of CALR Mutation Testing on Peripheral Blood To Paraffin Embedded Bone Marrow Tissue in Nonmutated JAK2 Primary Myelofibrosis and Essential Thrombocythemia
    Menke, Joshua
    Chehab, Farid
    Prakash, Sonam
    LABORATORY INVESTIGATION, 2015, 95 : 363A - 363A
  • [47] A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
    Bellosillo, B.
    Martinez-Aviles, L.
    Gimeno, E.
    Florensa, L.
    Longaron, R.
    Navarro, G.
    Salar, A.
    Espinet, B.
    Sole, F.
    Serrano, S.
    Besses, C.
    LEUKEMIA, 2007, 21 (06) : 1331 - 1332
  • [48] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [49] A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2015, 126 (23)
  • [50] A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Li, Li
    Pitou, Celine
    Nunes, Fabio P.
    Price, Gregory L.
    Giles, Jennifer L.
    D'Souza, Deborah N.
    Walgren, Richard A.
    Prchal, Josef T.
    LEUKEMIA RESEARCH, 2017, 61 : 89 - 95
12345